# Effects of FLASH Radiation on Cancer and the Immune Response

> **NIH NIH R01** · STANFORD UNIVERSITY · 2022 · $105,129

## Abstract

PROJECT ABSTRACT
Radiation therapy is a core treatment modality that benefits patients with many types of cancer,
and recent studies show that RT can enhance the efficacy of immune checkpoint blocking
antibodies by inducing immunogenic tumor cell death and “in situ vaccination”. We recently
discovered that higher doses of RT given over a smaller number of fractions ("accelerated
fractionated RT") can cure single tumors in mouse models and that such cures rely on
enhanced anti-tumor immune responses. Although the dose of RT was limited by damage to
surrounding tissues, these findings raised the prospect of more robust responses and even
cures of metastatic disease provided that we can understand how to optimize RT for maximum
synergy with immunotherapy and minimize collateral damage. Based on this premise, we began
developing a next-generation clinical radiation therapy platform that can deliver ultra-rapid
radiation (FLASH) and complete treatment in less than a second for extremely precise RT,
addressing the challenge of hitting moving targets like tumors and enabling safe delivery of
higher RT doses. We have already developed a unique preclinical FLASH irradiator for mice
and demonstrated enhanced tumor control and increased immune cell infiltration with FLASH
vs. conventional dose rate irradiation (i.e., sub-second vs. 5-minute delivery of the same
radiation doses) in a syngeneic subcutaneous tumor model. Prior studies in our lab and others
also demonstrated dramatically decreased normal organ injury with FLASH in multiple systems,
all of which have an inflammatory basis, including lung (fibrosis), brain (cognition and
neuroinflammation) and GI tract (intestinal crypt ablation and GI syndrome). This R01 diversity
supplement will support a new project, to be conducted by Dr. Soto, that is related to Aims 1
and 3 of the parent R01. One aim will examine the curative potential of FLASH radiation by
identifying a radiation dose at which local tumor cure is achieved in subcutaneous tumor mouse
models. This will build on Aim 1 of the parent R01 by further studying the therapeutic effect of
FLASH radiation, not in the context of tumor growth delay, but rather in the context of tumor
cure. The second aim will investigate the levels of activated TGF after FLASH radiation and
compare them to levels of activated TGF following CONV radiation. Activated TGF has been
shown to support tumor survival by enhancing DNA repair, suppressing the immune response,
and promoting a growth-favorable tumor microenvironment (6). This will build on Aim 3 of the
parent R01 by helping to understand a potential cellular mechanism for the efficacy of FLASH
radiation.

## Key facts

- **NIH application ID:** 10599538
- **Project number:** 3R01CA233958-04S1
- **Recipient organization:** STANFORD UNIVERSITY
- **Principal Investigator:** EDGAR G. ENGLEMAN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $105,129
- **Award type:** 3
- **Project period:** 2019-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10599538

## Citation

> US National Institutes of Health, RePORTER application 10599538, Effects of FLASH Radiation on Cancer and the Immune Response (3R01CA233958-04S1). Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/grant/nih/10599538. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*